First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308
monotherapy or in combination with chemotherapy in patients with certain types of advanced
solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and
immunogenicity of IBI308.